Muken Ross sold $51K of SOPH
Muken Ross (Chief Executive Officer) sold 9,838 shares of SOPHiA GENETICS SA (SOPH) at $5.22 on 2026-07-06 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosure updates the record of CEO share sales (9,838 shares at $5.2200; ~$51.4K total) and confirms the sale was executed under a pre-arranged 10b5-1 plan.
Market read
Traders may monitor for follow-on insider activity, but the filing alone does not indicate a new fundamental catalyst.
What to watch
The article lacks context on total planned sales, whether this is part of a larger tranche, and whether there were concurrent insider buys or material company updates.
Background
The article is a primary-source SEC Form 4 insider transaction disclosure for SOPHiA GENETICS.
Ticker impact
SOPHiA GENETICS CEO Muken Ross sold 9,838 shares in an open-market transaction on 2026-07-06 under a 10b5-1 plan.
Likely limited near-term impact; any reaction is more sentiment/flow-driven than fundamental.
The filing provides transaction size, price ($5.2200), and post-sale holdings, but no accompanying company-specific operational or guidance change.
Market effects
Minimal—this is a single-company insider transaction with no sector-wide catalyst.
None indicated.
None indicated.
Counterpoint
Even with a 10b5-1 plan, repeated insider selling can still coincide with perceived valuation risk or liquidity needs, potentially weighing on sentiment.
Key entities
- issuerSOPHiA GENETICS SA
Company whose CEO executed an open-market sale disclosed on Form 4.
- insiderMuken Ross
Chief Executive Officer and director who sold shares under a 10b5-1 plan.
